HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson
HeartSciences (Nasdaq: HSCS) has announced an upcoming investor webinar scheduled for Wednesday, May 14, 2025, at 2:00 p.m. EDT. The event will feature CEO Andrew Simpson who will present and conduct a Q&A session focusing on the company's AI-powered ECG/EKG technology platform. The webinar will provide insights into HeartSciences' mission to transform early heart disease detection and its market opportunities. Simpson will also discuss a Regulation A investment opportunity available to qualified investors.
HeartSciences (Nasdaq: HSCS) ha annunciato un webinar per investitori previsto per mercoledì 14 maggio 2025 alle 14:00 EDT. L'evento vedrà la partecipazione del CEO Andrew Simpson, che presenterà e condurrà una sessione di domande e risposte incentrata sulla piattaforma tecnologica ECG/EKG basata su intelligenza artificiale dell'azienda. Il webinar offrirà approfondimenti sulla missione di HeartSciences di rivoluzionare la diagnosi precoce delle malattie cardiache e sulle opportunità di mercato. Simpson parlerà anche di un'opportunità di investimento regolamentata disponibile per investitori qualificati.
HeartSciences (Nasdaq: HSCS) ha anunciado un próximo seminario web para inversores programado para el miércoles 14 de mayo de 2025 a las 2:00 p.m. EDT. El evento contará con la participación del CEO Andrew Simpson, quien presentará y dirigirá una sesión de preguntas y respuestas centrada en la plataforma tecnológica de ECG/EKG impulsada por IA de la compañía. El seminario web ofrecerá perspectivas sobre la misión de HeartSciences de transformar la detección temprana de enfermedades cardíacas y sus oportunidades de mercado. Simpson también hablará sobre una oportunidad de inversión bajo la Regulación A disponible para inversores calificados.
HeartSciences (나스닥: HSCS)는 2025년 5월 14일 수요일 오후 2시 EDT에 예정된 투자자 웨비나를 발표했습니다. 이번 행사에는 CEO 앤드류 심슨이 참여하여 회사의 AI 기반 ECG/EKG 기술 플랫폼에 대한 발표와 질의응답 세션을 진행할 예정입니다. 웨비나에서는 HeartSciences가 조기 심장병 진단을 혁신하려는 사명과 시장 기회에 대한 통찰을 제공할 것입니다. 또한 심슨은 적격 투자자를 위한 Regulation A 투자 기회에 대해서도 논의할 예정입니다.
HeartSciences (Nasdaq : HSCS) a annoncé un prochain webinaire pour investisseurs prévu le mercredi 14 mai 2025 à 14h00 EDT. L'événement mettra en vedette le PDG Andrew Simpson, qui présentera et animera une session de questions-réponses axée sur la plateforme technologique ECG/EKG alimentée par l'IA de l'entreprise. Le webinaire offrira un aperçu de la mission de HeartSciences visant à transformer la détection précoce des maladies cardiaques ainsi que de ses opportunités de marché. Simpson discutera également d'une opportunité d'investissement en vertu du Règlement A, disponible pour les investisseurs qualifiés.
HeartSciences (Nasdaq: HSCS) hat ein bevorstehendes Investoren-Webinar angekündigt, das für Mittwoch, den 14. Mai 2025, um 14:00 Uhr EDT geplant ist. Bei der Veranstaltung wird CEO Andrew Simpson eine Präsentation halten und eine Fragerunde durchführen, die sich auf die KI-gestützte ECG/EKG-Technologieplattform des Unternehmens konzentriert. Das Webinar bietet Einblicke in die Mission von HeartSciences, die frühzeitige Erkennung von Herzkrankheiten zu revolutionieren, sowie in die Marktchancen. Simpson wird auch eine Regulation A-Investitionsmöglichkeit für qualifizierte Investoren erläutern.
- None.
- None.
Southlake, TX, May 08, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that it will host a live investor webinar on Wednesday, May 14, 2025, at 2:00 p.m. EDT | 11:00 a.m. PDT, featuring a presentation and Q&A session with CEO Andrew Simpson.
Register Now
To attend the webinar and participate in the live Q&A, please register through:
HeartSciences Investor Webinar May 14th at 2:00 pm EDT
This is an opportunity for investors to gain insight into HeartSciences’ mission, market opportunity, and its AI-ECG platform, which is designed to significantly enhance the diagnostic utility of the standard ECG. The platform aims to help clinicians detect heart disease earlier, faster, and at the point of care. CEO Andrew Simpson will also discuss the Company’s current Regulation A investment opportunity, which offers qualified investors access to investment in the Company on terms typically not available through public markets.
About HeartSciences
HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG’s clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and intends to provide these AI-ECG algorithms on a device agnostic cloud-based solution as well as a low-cost ECG hardware platform. Working with clinical experts, HeartSciences ensures that all solutions are designed to work within existing clinical care pathways, making it easier for clinicians to use AI-ECG technology to improve their patient's care and lead to better outcomes. HeartSciences' first product candidate for FDA clearance, the MyoVista® wavECG™, or the MyoVista®, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista® also provides conventional ECG information in the same test.
For more information, please visit: https://www.heartsciences.com. X: @HeartSciences
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences' beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences' Annual Report on Form 10-K for the fiscal year ended April 30, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 29, 2024, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2024, filed with the SEC on September 12, 2024, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended October 31, 2024, filed with the SEC on December 16, 2024, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2025, filed with the SEC on March 13, 2024 and in HeartSciences' other filings with the SEC at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
HeartSciences is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Tier II of Regulation A. Before making any investment, you are urged to read the Final Offering Circular carefully for a more complete understanding of the issuer and the offering. The securities offered by HeartSciences are highly speculative. Investing in these securities involves significant risks. There is no guarantee of return, and you should only invest money that you can afford to lose. Use proper risk management when considering this investment. For additional information on HeartSciences, the offering and risk factors related to the offering, please review the Form 1-A offering circular that can be found by searching for HeartSciences under Filings/Company filings search on www.sec.gov.
Investor Relations:
Integrous Communications
Mark Komonoski
Partner
Phone: 877-255-8483
Email: mkomonoski@integcom.us
Media Contact:
HeartSciences
Gene Gephart
Phone: +1-682-244-2578 Ext. 2024
Email: info@heartsciences.com
FAQ
When is HeartSciences (HSCS) hosting its investor webinar in May 2025?
Who will be presenting at the HeartSciences (HSCS) May 2025 investor webinar?
What topics will be covered in the HeartSciences (HSCS) May 2025 investor webinar?
What is the main technology focus of HeartSciences (HSCS)?
